Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response. The long-term mortality rate of steroid-refr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yamin Tan, Haowen Xiao, Depei Wu, Yi Luo, Jianping Lan, Qifa Liu, Kang Yu, Jimin Shi, Jingsong He, Weiyan Zheng, Xiaoyu Lai, Yuanyuan Zhu, Kaili Du, Yishan Ye, Yanmin Zhao, Gaofeng Zheng, Yongxian Hu, Xiaoyan Han, Yanlong Zheng, Guoqing Wei, Zhen Cai, He Huang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis Group 2017-03-01
Sarja:OncoImmunology
Aiheet:
basiliximab
etanercept
hematopoietic stem cell transplantation
steroid-refractory acute gvhd
Linkit:http://dx.doi.org/10.1080/2162402X.2016.1277307
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia